Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status-Reference-Cited by-同舟云学术

Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status

Published:2021-09 Issue: Volume:155 Page:1-12
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Hein Alexander^ORCID,Hartkopf Andreas D.,Emons Julius^ORCID,Lux Michael P.^ORCID,Volz Bernhard,Taran Florin-Andrei^ORCID,Overkamp Friedrich,Hadji Peyman,Tesch Hans,Häberle Lothar,Ettl Johannes,Lüftner Diana^ORCID,Wurmthaler Lena A.,Wallwiener Markus,Müller Volkmar^ORCID,Beckmann Matthias W.,Belleville Erik,Wimberger Pauline,Hielscher Carsten,Kurbacher Christian M.,Wuerstlein Rachel,Thomssen Christoph,Untch Michael,Fasching Peter A.^ORCID,Janni Wolfgang,Fehm Tanja N.,Wallwiener Diethelm,Brucker Sara Y.^ORCID,Schneeweiss Andreas,Kolberg Hans-Christian

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference34 articles.

1. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update;Wolff;J Clin Oncol,2013

2. Human epidermal growth factor receptor 2 testing in breast cancer: American society of Clinical oncology/college of American pathologists clinical practice guideline focused update;Wolff;J Clin Oncol,2018

3. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene;Slamon;Science,1987

4. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer;Slamon;Science,1989

5. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update;Allison;J Clin Oncol,2020

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incidence and Prognostic Values in Human Epidermal Growth Factor Receptor 2-Low Expression Metastatic Breast Cancer in Southeast Asian Population: A 10-Year Retrospective Study;JCO Global Oncology;2024-09

2. Real-world treatment patterns and outcomes in patients with HR+/HER2− metastatic breast cancer treated with chemotherapy in the United States;ESMO Open;2024-09

3. The impact of human epidermal growth factor receptor-2 (low) status on the efficacy of first line cyclin-dependent kinase 4/6 inhibitors in advanced breast cancer;Medicine;2024-07-26

4. Clinicopathological Features and Long-Term Prognostic Role of Human Epidermal Growth Factor Receptor-2 Low Expression in Chinese Patients with Early Breast Cancer: A Single-Institution Study;BIOMED ENVIRON SCI;2024

5. Attrition in the First Three Therapy Lines in Patients with Advanced Breast Cancer in the German Real-World PRAEGNANT Registry;Geburtshilfe und Frauenheilkunde;2024-05